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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Yestimun
® and defence against pathogens in the upper respiratory tract 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant to Article 
13(5)  of  Regulation  (EC)  No  1924/2006  via  the  Competent  Authority  of  Germany,  the  Panel  on  Dietetic 
Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to Yestimun
® and defence against pathogens in the upper respiratory tract. The food that is 
the subject of the health claim, Yestimun
®, which consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell 
wall, is sufficiently characterised. The claimed effect, defence against pathogens in the upper respiratory tract, is 
a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect 
relationship  has  not  been  established  between  the  consumption  of  Yestimun
®  ((1,3)-(1,6)-β-D-glucans  from 
brewer’s yeast cell wall) and defence against pathogens in the upper respiratory tract. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant 
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of  Germany, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 
the scientific substantiation of a health claim related to Yestimun
® and defence against pathogens in 
the upper respiratory tract. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is Yestimun
®, which consists of (1,3)-(1,6)-β-D-
glucans  from  brewer’s  yeast  cell  wall.  The  Panel  considers  that  Yestimun
®  is  sufficiently 
characterised. 
The claimed effect proposed by the applicant is related to the defence against pathogens in the upper 
respiratory tract. The target population proposed by the applicant is adults in the general population. 
The  Panel  considers  that  defence  against  pathogens  in  the  upper  respiratory  tract  is  a  beneficial 
physiological effect. 
The applicant performed a literature search in Medline for publications in English and German using 
keywords, “like yeast beta-glucan, immune system, oral, human, study, trial”. As directly pertinent to 
the claim, the applicant identified through the literature search one published randomised controlled 
trial (RCT) and provided two unpublished RCTs. 
These studies investigated the effect of Yestimun
® on the frequency of occurrence of common cold 
episodes  or  upper  respiratory  tract  infections,  on  the  duration  of  the  infection  and  on  symptom 
severity scores. 
The Panel notes that the evidence provided by the applicant does not establish the validity of the 
questionnaires and the criteria used in these studies to assess the incidence, duration or the severity of 
common cold episodes. The Panel also notes the limitations in the statistical analyses of these studies 
(e.g. exclusion of one study site from statistical analysis without  appropriate justification and the 
requested re-analysis of the data was not presented for one of the studies, the multi-centre design was 
not taken into account in the statistical analyses of two of the studies and no account was taken for 
multiplicity of “primary outcomes” in one of the studies). 
The Panel considers that no conclusions can be drawn for the scientific substantiation of the claim 
from any of the human intervention studies provided by the applicant. 
The Panel notes that in the absence of an effect of Yestimun
® in humans on defence against pathogens 
in the upper respiratory tract the submitted human, animal and in vitro studies pertaining to a possible 
mechanism by which Yestimun
® could exert the claimed effect do not provide any scientific evidence 
for the substantiation of the claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption  of  Yestimun
®  ((1,3)-(1,6)-β-D-glucans  from  brewer’s  yeast  cell  wall)  and  defence 
against pathogens in the upper respiratory tract. 
 Yestimun
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of health claims made on foods.  As a 
rule, health claims are prohibited  unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular,  Article 13(5)  of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to chi ldren’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 20/08/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed scientific evidence and includes a request for the protection of proprietary data. 
  On 04/10/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 22/10/2012, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 25/10/2012. 
  On 14/12/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 18/12/2012 and restarted on 02/01/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
  On  08/01/2013,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 07/01/2013). 
  During  its  meeting  on  21/03/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Yestimun
® and 
defence against pathogens in the upper respiratory tract. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: Yestimun
® and defence against 
pathogens in the upper respiratory tract. 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of Yestimun
®, a positive assessment of its safety, nor a decision on whether Yestimun
® is, 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Yestimun
® and defence against pathogens in the upper respiratory tract 
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or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. Yestimun
® and defence against pathogens in the upper respiratory tract 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Leiber GmbH, Hafenstraße 24, 49565 Bramsche, Germany. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (manufacturing process). 
Food/constituent as stated by the applicant 
According to the applicant, the food, which is the subject of the claim, is Yestimun
®, which is (1,3)-
(1,6)-β-D-glucan of brewer’s yeast cell wall (100 % Saccharomyces cerevisiae). 
Health relationship as claimed by the applicant 
According to the applicant, β-glucans of the yeast cell wall are dietary fibres that have been shown to 
induce immunostimulating responses in animals and humans after oral administration. Yestimun
® 
causes a reduction of the number of common cold episodes during the cold season in normal subjects, 
which  was  shown  in  two  independent  studies.  Common  colds  are  caused  by  viruses,  which  are 
pathogens that are eliminated by the body’s defence mechanisms. The interaction of yeast β-glucan 
particles, like Yestimun
®, with the Peyer’s patches in the intestine alerts the immune system resulting 
in reduced numbers of common cold episodes and, thus, helps maintaining the body’s defence against 
pathogens. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Daily administration of 
Yestimun
® helps to maintain the body´s defence against pathogens”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, 0.45 g of Yestimun
® should be administered twice daily in order to obtain 
the claimed effect. The target population proposed by the applicant is adults in the general population. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food that is the subject of the health claim is Yestimun
®. 
Yestimun
® consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall (100 % Saccharomyces 
cerevisiae)  (about  90 %  by  weight).  β-Glucans  are  polysaccharides  consisting  of  a  backbone  of 
D-glucose subunits linked by (1,3)-β-glucosidic bonds with irregular β-(1,6)-linked glucosidic side 
chains  of  various  length.  Information  about  the  stability  of  the  product,  about  the batch-to-batch 
variability  of  the  (1,3)-(1,6)-β-D-glucan  content  in  different  batches  of  Yestimun
®  and  about  the 
manufacturing process has been provided by the applicant. β-Glucans are measureable in foods by 
established methods. 
The Panel considers that the food, Yestimun
® ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall), 
which is the subject of the health claim, is sufficiently characterised. Yestimun
® and defence against pathogens in the upper respiratory tract 
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2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is related to the defence against pathogens in the upper 
respiratory tract. The target population proposed by the applicant is adults in the general population. 
The  Panel  considers  that  defence  against  pathogens  in  the  upper  respiratory  tract  is  a  beneficial 
physiological effect. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline for publications in English and German using 
keywords, “like yeast beta-glucan, immune system, oral, human, study, trial”. Studies were included if 
they used insoluble yeast β-glucans and investigated the incidence of common cold infections in 
humans or immunological parameters in animal and in ex vivo models. Exclusion criteria comprised 
studies  using  β-glucans  other  than  S.  cerevisiae-derived  β-glucans  and  studies  with  parenteral 
administration. 
As directly pertinent to the claim, the applicant identified through the literature search one published 
randomised  controlled  trial  (RCT)  (Feldman  et  al.,  2009)  and  provided  two  unpublished  RCTs 
(Graubaum, 2007, unpublished; Bothe, 2011, unpublished). 
In  the  randomised,  double-blind,  placebo-controlled,  seven-centre  study  by  Bothe  (2011, 
unpublished), 224 subjects (mean age: 46.0±15.7 years; 146 female) with recurrent upper respiratory 
tract infections were randomised to consume daily either 900 mg (2 x 450 mg) Yestimun
® (n=112) or 
placebo (maltodextrin, n=112) for 16 weeks (from October 2010 to May 2011). The primary endpoint 
of the study was the reduction in the number of common cold episodes per subject during the study 
period. Secondary outcomes were the severity of an entire common cold episode, the severity of an 
episode in the first two days, the severity of the episode at the “Episode Visit” (at the fifth day of each 
common cold episode), the duration of a cold episode and the use of antibiotics and analgesics. 
Subjects rated daily the severity of 10 pre-defined symptoms (headache, joint pain, sore throat, feeling 
of lump in the throat/difficulty swallowing, hoarseness, cough, running nose, nasal congestion, cold-
related  sleeping  difficulties,  “fever”  (not  defined))  on  a  4-level  Likert  item  (symptom-free,  mild, 
moderate and severe symptoms, except for “fever” which was always rated as severe) in diaries.  
A common cold episode was defined by the occurrence of at least two of the following symptoms 
rated at least as mild (2 on the 4-point item): sore throat, feeling of lump in the throat/difficulty 
swallowing, hoarseness, cough, running nose and nasal obstruction. Upon occurrence of a common 
cold episode, a composite score was calculated to assess the severity of the common cold episode.  
Following a request from EFSA to provide a rationale for the use of this questionnaire to assess the 
incidence,  duration  and  severity  of  common  cold  episodes,  the  applicant  referred  to  the  Jackson 
criteria. These criteria include the rating of the following common cold symptoms on a 4-point item: 
sneezing, headache, malaise, chilliness, nasal discharge, nasal obstruction, sore throat and cough. A 
common cold episode is defined as a symptom score of 14 plus the subject’s subjective feeling of 
illness  or  increased  nasal  discharge on three out of six days. For symptom scores <14, both the 
subject’s subjective feeling of illness and an increased nasal discharge on three out of six days are 
required for diagnosis (Jackson et al., 1958). 
The  Panel  notes  that  both  the  questionnaire  and  the  criteria  used  in  the  study  by  Bothe  (2011, 
unpublished) to assess the incidence, duration and severity of common cold episodes differ from those 
developed by Jackson et al. (1958). The Panel considers that the evidence provided by the applicant 
does not establish the validity of the questionnaire and the criteria used in the study to assess the 
incidence, duration or the severity of common cold episodes.  Yestimun
® and defence against pathogens in the upper respiratory tract 
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Data were analysed by the Mann Whitney U test or by the χ
2
 test if proportions were analysed. In one 
study site, the average number of common cold episodes was statistically significantly different from 
the other study sites and lower than the expected number of common cold episodes per subject. Data 
from this study site (60 subjects) were removed from data analyses. Upon a request from EFSA to re-
analyse  the  data  taking  into  account  this  study  site,  the  applicant  explained  that  this  centre  was 
excluded from analysis owing to possible underreporting of the outcome but did not provide the 
requested re-analysis of the data.  
The Panel notes that the evidence provided by the applicant does not establish the validity of the 
questionnaire and the criteria used in the study to assess the incidence, duration or the severity of 
common cold episodes. The Panel also notes that removing one centre from data analysis owing to 
possible underreporting which might have occurred in this site is not an appropriate justification for 
removing the site from the statistical analysis, that the results of the requested re-analysis of the data 
including this centre were not presented and that the statistical analysis did not account for the multi-
centre design of the study. The Panel considers that no conclusions can be drawn from this study for 
the scientific substantiation of the claim. 
In  the  randomised,  double-blind,  placebo-controlled,  five-centre  study  by  Graubaum  (2007, 
unpublished), 100 healthy adult subjects (median age: 46.3 years, 58 women) with recurrent upper 
respiratory tract infections were randomised to consume daily either 900 mg (2 x 450 mg, n=50) 
Biolex
® Beta HP capsules (identical to Yestimun
®) or placebo (micro-crystalline cellulose, n=50) for 
26 weeks (from November 2006 until June 2007). Doses of Biolex
® Beta HP or placebo had to be 
doubled upon occurrence of a common cold episode for the duration of the episode. The primary 
outcome of the study was the frequency of occurrence of common cold episodes. Secondary outcomes 
included the frequency of occurrence of individual common cold symptoms on the first day of the 
episode, severity of common cold symptoms expressed as composite common cold scores on days 1 to 
5 of the episode, relative changes in severity of common cold symptoms expressed as composite 
common cold scores from day 1 to day 3 and from day 1 to day 5, and the “therapeutic success” of 
doubling  the  dose  of  Biolex
®  Beta  HP  or  placebo  upon  occurrence  of  a  common  cold  episode 
(=necessary  intervention  period  until  the  first  symptom  free  day  of  individual  common  cold 
symptoms). The Panel notes that for the present evaluation only outcomes related to the single dose of 
Biolex
® Beta HP were considered further and not those outcomes which were the target for treatment 
by doubling the dose of the intervention. 
Subjects rated daily the severity of six pre-defined symptoms (general feeling of illness, headache 
and/or joint pain, sore throat and/or difficulty in swallowing, hoarseness and/or coughing, watery 
nasal discharge and cold related sleeping difficulties) on a 3-level Likert item (no symptoms, mild 
symptoms, severe symptoms).  
A common cold episode was defined by the occurrence of at least one of the following symptoms: 
headache  and/or  joint  pain;  sore  throat  and/or  difficulty  swallowing;  hoarseness  and/or  cough; 
rhinorrhoea; cold related sleep difficulty. Upon occurrence of a common cold episode, subjects also 
had to present themselves to the investigator, who documented the symptoms experienced by subjects 
at the beginning of the episode and five days thereafter. A composite score was calculated to assess 
the severity of the common cold episode. 
As for the study by Bothe (2011, unpublished), the Panel considers that the evidence provided by the 
applicant does not establish the validity of the questionnaire and the criteria used in the study to 
assess the incidence or the severity of common cold episodes.  
Data were analysed using the Mann-Whitney U test. The χ
2 test was used when proportions were 
analysed. A non-parametric, multivariate analysis for repeated measures was used in the longitudinal 
analysis of secondary outcomes. Post-hoc analyses were performed based on episodes that occurred in 
the winter months (November to March, first half of the study) to avoid error that might have arisen Yestimun
® and defence against pathogens in the upper respiratory tract 
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owing to possible misdiagnosis of allergic rhinitis as common cold infections during the summer 
months.  
The Panel notes that the evidence provided by the applicant does not establish the validity of the 
questionnaire and the criteria used in the study to assess the incidence or the severity of common cold 
episodes. The Panel also notes that the statistical analysis did not account for the multi-centre design 
of  the  study  and  that  avoidance  of  possible  misdiagnosis  is  not  an  appropriate  justification  for 
conducing post-hoc analyses. The Panel considers that no conclusions can be drawn from this study 
for the scientific substantiation of the claim.  
A double-blind, placebo-controlled, randomised intervention  (Feldman et al., 2009) in 40 healthy 
adults investigated the effects of consuming 500 mg/day Wellmune
® (70 % yeast beta-glucan; n=21) 
for  90  days  vs.  placebo  (rice  flour;  n=19)  on  symptomatic  respiratory  tract  infections.  Upon 
occurrence of a respiratory symptom, subjects were asked to present themselves to the investigators 
for  diagnosis  and  were  provided  with  symptom  diaries.  No  information  was  provided  about  the 
criteria used in the diagnosis of respiratory tract infections or about the symptom diaries used. 
Endpoints  included  the  number  of,  and  total  days  with,  symptomatic  respiratory  tract  infections 
(defined as common cold, influenza, pharyngitis), the average duration of a symptomatic respiratory 
tract infection, symptom severity of 13 pre-defined symptoms, and the number of missed school/work 
days. A total of 12 subjects dropped out from the study. Changes from baseline were analysed using 
repeated measures analysis of variance (RM-ANOVA) without correcting for multiple comparisons 
made. 
The Panel notes that the criteria used to diagnose respiratory tract infections are unclear and that 
information about the symptom diaries used in the study is missing. The Panel also notes the small 
sample size of the study, the high drop-out rate and that the statistical analysis did not take into 
account  the  multiplicity  of  “primary  outcomes”.  The  Panel  considers  that  no  conclusions  can be 
drawn from this study for the scientific substantiation of the claim.  
The Panel notes that no human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. 
With respect to the potential mechanism by which  Yestimun
® could exert the claimed effect the 
applicant provided two human studies (Döll et al., 2005; Lehne et al., 2006), seven animal studies 
(Fleischer et al., 2000; Fleischer et al., 2001; Vetvicka et al., 2002; Hong et al., 2004; Li et al., 2005; 
Małaczewska et al., 2010; Wójcik, 2010), four in vitro studies (Seljelid et al., 1981; Sandula et al., 
1995; Kankkunen et al., 2010; Goodridge et al., 2011) and seven review publications (Bohn and 
BeMiller,  1995;  Kogan,  2000; Tzianabos, 2000; Brown and Gordon, 2005; Zekovic et al., 2005; 
Akramiene et al., 2007; Volman et al., 2008).  
The Panel notes that in the absence of an effect of Yestimun
® in humans on defence against pathogens 
in the upper respiratory tract the submitted human, animal and in vitro studies pertaining to a possible 
mechanism by which Yestimun
® could exert the claimed effect do not provide any scientific evidence 
for the substantiation of the claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption  of  Yestimun
®  ((1,3)-(1,6)-β-D-glucans  from  brewer’s  yeast  cell  wall)  and  defence 
against pathogens in the upper respiratory tract. Yestimun
® and defence against pathogens in the upper respiratory tract 
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food, Yestimun
® ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) which is the 
subject of the health claim, is sufficiently characterised. 
  The claimed effect proposed by the applicant is related to the defence against pathogens in the 
upper  respiratory  tract.  The  target  population  proposed  by  the  applicant  is  adults  in  the 
general population. Defence against pathogens in the upper respiratory tract is a beneficial 
physiological effect. 
  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of 
Yestimun
®  ((1,3)-(1,6)-β-D-glucans  from  brewer’s  yeast  cell  wall)  and  defence  against 
pathogens in the upper respiratory tract. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Yestimun
® and defence against pathogens in the upper respiratory tract 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0364_DE). October 
2012. Submitted by Leiber GmbH. 
REFERENCES 
Akramiene D, Kondrotas A, Didziapetriene J and Kevelaitis E, 2007. Effects of beta-glucans on the 
immune system. Medicina (Kaunas), 43, 597-606. 
Bohn JA and BeMiller JN, 1995. (1→3)-β-D-Glucans as biological response modifiers: a review of 
structure-functional activity relationships. Carbohydrate Polymers, 28, 3-14. 
Bothe G, 2011, unpublished. Double-blind, randomized, placebo-controlled clinical study to evaluate 
efficacy and safety of Yestimun® in subjects with increased susceptibility to common cold. 
Brown GD and Gordon S, 2005. Immune recognition of fungal beta-glucans. Cellular Microbiology, 
7, 471-479. 
Döll M, Hauss R and Spermezan R, 2005. Anwendungsbeobachtung: Immunmodulierende Wirkung 
von (1-3),(1-6)- -D-Glucan – Gezeigt an der Neopterin- und b-Defensin-Synthese. Naturheilpraxis, 
5. 
Feldman S, Schwartz HI, Kalman DS, Mayers A, Kohrman HM, Clemens R and Krieger DR, 2009. 
Randomized phase II clinical trials of Wellmune WGP® for immune support during cold and flu 
season. The Journal of Applied Research, 9, 30-42. 
Fleischer LG, Gerber G, Liezenga RW, Lippert E, Scholl MA and Westphal G, 2000. Blood cells and 
plasma  proteins  of  chickens  fed  a  diet  supplemented  with  (1-->3),(1-->6)-beta-D-glucan  and 
enrofloxacin. Archiv für Tierernährung, 53, 59-73. 
Fleischer  LG,  Gerber  G,  Gremmels  HD,  Lippert  E  and  Westphal  G,  2001.  Experimentelle 
Modelluntersuchungen  zum  Einsatz  von  (1-->3),(1-->6)-beta-D-Glucan  aus  Saccharomyces 
cerevisiae als "Health Ingredient". Fibiona Health Products GmbH. 
Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, 
Danielson ME, Weiss A, Vasilakos JP and Underhill DM, 2011. Activation of the innate immune 
receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature, 472, 471-475. Yestimun
® and defence against pathogens in the upper respiratory tract 
 
 
11  EFSA Journal 2013;11(4):3159 
Graubaum  HJ,  2007,  unpublished.  Double-blind,  randomized,  placebo-controlled,  multicentric 
nutrition  study  to  prove  the  efficacy  and  safety  of  Biolex®  Beta  HP  as  a  prophylactic  and 
therapeutic for common colds. 
Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK and Ross GD, 
2004. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity 
of antitumor monoclonal antibodies in murine tumor models. Journal of Immunology, 173, 797-
806. 
Jackson GG, Dowling HF, Spiesman IG and Boand AV, 1958. Transmission of the common cold to 
volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Archives of 
Internal Medicine, 101, 267-278. 
Kankkunen P, Teirilä L, Rintahaka J, Alenius H, Wolff H and Matikainen S, 2010. (1,3)-beta-glucans 
activate both dectin-1 and NLRP3 inflammasome in human macrophages. Journal of Immunology, 
184, 6335-6342. 
Kogan G, 2000. (1→3,1→6)-β-D-glucans of yeasts and fungi and their biological activity. In: Studies 
in  Natural  Products  Chemistry,  Volume  23:  Bioactive  natural  Products  (Part  D).  Ed  Atta-ur-
Rahman. Elsevier, Amsterdam, NL, 107-152. 
Lehne  G,  Haneberg  B,  Gaustad  P,  Johansen  PW,  Preus  H  and  Abrahamsen  TG,  2006.  Oral 
administration  of  a  new  soluble  branched  beta-1,3-D-glucan  is  well  tolerated  and  can  lead  to 
increased  salivary  concentrations  of  immunoglobulin  A  in  healthy  volunteers.  Clinical  and 
Experimental Immunology, 143, 65-69. 
Li J, Xing J, Li D, Wang X, Zhao L, Lv S and Huang D, 2005. Effects of beta-glucan extracted from 
Saccharomyces  cerevisiae  on  humoral  and  cellular  immunity  in  weaned  piglets.  Archives  of 
Animal Nutrition, 59, 303-312. 
Małaczewska  J,  Wójcik  R,  Jung  L  and  Siwicki  AK,  2010.  Effect  of  Biolex  β-HP  on  selected 
parameters of specific and non-specific humoral and cellular immunity in rats. Bulletin of the 
Veterinary Institute in Pulawy, 54, 75-80. 
Sandula J, Machova E and Hribalova V, 1995. Mitogenic activity of particulate yeast beta-(1-->3)-D-
glucan and its water-soluble derivatives. International Journal of Biological Macromolecules, 17, 
323-326. 
Seljelid  R,  Bögwald  J  and  Lundwall  Å,  1981.  Glycan  stimulation  of  macrophages  in  vitro. 
Experimental Cell Research, 131, 121-129. 
Tzianabos AO, 2000. Polysaccharide immunomodulators as therapeutic agents: structural aspects and 
biologic function. Clinical Microbiology Reviews, 13, 523-533. 
Vetvicka V, Terayama K, Mandeville R, Brousseau P, Kournikakis B and Ostroff G, 2002. Pilot 
study: Orally-administered yeast β1,3-glucan prophylactically protects against anthrax infection 
and cancer in mice. Journal of the American Nutraceutical Association, 5, 5-9. 
Volman JJ, Ramakers JD and Plat J, 2008. Dietary modulation of immune function by beta-glucans. 
Physiology and Behavior, 94, 276-284. 
Wójcik  R,  2010.  Effect  of  Biolex  Beta-HP  on  phagocytic  activity  and  oxidative  metabolism  of 
peripheral  blood  granulocytes  and  monocytes  in  rats  intoxicated  by  cyclophosphamide.  Polish 
Journal of Veterinary Sciences, 13, 181-188. 
Zekovic DB, Kwiatkowski S, Vrvic MM, Jakovljevic D and Moran CA, 2005. Natural and modified 
(1-->3)-beta-D-glucans  in  health  promotion  and  disease  alleviation.  Critical  Reviews  in 
Biotechnology, 25, 205-230. 
 Yestimun
® and defence against pathogens in the upper respiratory tract 
 
 
12  EFSA Journal 2013;11(4):3159 
GLOSSARY AND ABBREVIATIONS 
RM-ANOVA  Repeated measures analysis of variance 
RCT  Randomised controlled trial 